Lilly moves obesity drug to late-stage trials after it shows promise – Reuters
- Lilly moves obesity drug to late-stage trials after it shows promise Reuters
- Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study CNBC
- Lilly’s new weight loss drug shows promise in mid-stage trial NBC News
- Eli Lilly’s Eloralintide Matches Zepbound’s Weight Loss in Mid-Stage Obesity Trial Bloomberg.com
- Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3 Fierce Biotech
Source: Air Tools